Navigation Links
Seroquel's First- and Second-Line Patient Share Has Grown Since Last Year's Analysis of Prescribing Trends in Bipolar Disorder

Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources

Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years

WALTHAM, Mass., June 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel's first-line patient share grew two percent since last year's patient-level claims data analysis of prescribing trends in bipolar disorder. During this same time period other atypicals (with the exception of Pfizer's Geodon) lost first-line patient share which suggests that Seroquel's better penetration of first-line therapy came at the expense of others in the atypical class such as Bristol-Myers Squibb/Otsuka's Abilify and Eli Lilly's Zyprexa.

Although surveyed psychiatrists rate the overall attributes of Abilify higher than Seroquel/Seroquel XR, surveyed primary care physicians' assessment of these two agents is the opposite. Despite the advantage that surveyed psychiatrists give to Abilify over Seroquel on side-effect and safety attributes, Abilify's patient share is second to that of Seroquel in both first- and second-line therapy.

The new report entitled Treatment Algorithms in Bipolar Disorder also finds that although risperidone is now available in generics there is no clear evidence of its expanded uptake in early lines of therapy. Approximately 15 percent of surveyed physicians do not prescribe generic risperidone first-line and only one-third of surveyed physicians estimate that they prescribe generic risperidone first-line to more than half of their bipolar patients.

By pairing patient-level claims data with primary survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

"Our analysis of patient-flow to Seroquel XR shows that 30 percent of the patients who take it after another agent previously received Seroquel, indicating that Seroquel XR continues to garner a major portion of its business in patients using it as a replacement for Seroquel. However, approximately one-third of surveyed physicians plan to use Seroquel XR more often in the first-line over the next two years, which suggests that competitors will need to position themselves to combat Seroquel XR's growing use as a first-line treatment," stated Madhuri Borde, Ph.D., product director of Treatment Algorithms at Decision Resources.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
2. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
3. World fertility experts to meet in Montreal - IVF and IVM patients to provide first-person accounts at 14th World Congress
4. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Fred Hutchinson Cancer Research Center Announces the First-Ever Expedition to an Unclimbed Mountain in the Name of Cancer Research
7. Y-ME Illinois Hosts the First-Ever BIG Night Out - Indulgence for a Cause
8. TriWest and Alaska VA Hosted First-Ever PTSD State-Wide Seminars to Reach Rural Health Care Providers
9. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
10. Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest
11. Cardinal Health To Announce First-Quarter Results on November 5
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to MAP ... the two groups began in 2014 with Vitalalert pledging a portion of every purchase ... in 1954 and is an international Christian-based health organization whose mission is to “advance ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ... and CEO, will discuss corporate updates at the 27 th ... York on Wednesday, December 2, 2015 at 1 ... Relations, and then the link to the event. Participants should ... to visit the site and download any streaming media software ...
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... November 25, 2015 - Will ... Education (CME) --> - Will ... Medical Education (CME) --> - ... Continuing Medical Education (CME) Elsevier ... and services, will feature latest diagnostic imaging textbooks and decision support ...
Breaking Medicine Technology: